{"id":"primidone","rwe":[{"pmid":"41897256","year":"2026","title":"Comparative Efficacy of Acupuncture Therapy in Primary Essential Tremor: A Network Meta-Analysis and Systematic Review.","finding":"","journal":"Healthcare (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41833537","year":"2026","title":"A Systematic Review of Clinically Significant Drug-Drug Interactions With Phenobarbital and Primidone.","finding":"","journal":"Pharmacotherapy","studyType":"Clinical Study"},{"pmid":"41806836","year":"2026","title":"TRPM3 mediates spontaneous pain and mechanical allodynia in a mouse model of chronic orofacial neuropathy.","finding":"","journal":"Cell reports. Medicine","studyType":"Clinical Study"},{"pmid":"41795508","year":"2026","title":"Enteric virus and pharmaceutical and personal care product attenuation in a bench-scale ozone-soil aquifer treatment process.","finding":"","journal":"The Science of the total environment","studyType":"Clinical Study"},{"pmid":"41556478","year":"2026","title":"Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.","finding":"","journal":"Movement disorders : official journal of the Movement Disorder Society","studyType":"Clinical Study"}],"_fda":{"id":"373a4c73-f3c2-2c93-e063-6294a90ad5eb","set_id":"0193c0a4-f593-609c-e063-6294a90aaa68","openfda":{"nui":["N0000175753","N0000008486"],"upc":["0372789178301","0372789177014"],"unii":["13AFD7670Q"],"route":["ORAL"],"rxcui":["96304","198150"],"spl_id":["373a4c73-f3c2-2c93-e063-6294a90ad5eb"],"brand_name":["Primidone"],"spl_set_id":["0193c0a4-f593-609c-e063-6294a90aaa68"],"package_ndc":["72789-178-30","72789-177-30"],"product_ndc":["72789-177","72789-178"],"generic_name":["PRIMIDONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Decreased Central Nervous System Disorganized Electrical Activity [PE]"],"substance_name":["PRIMIDONE"],"pharm_class_epc":["Anti-epileptic Agent [EPC]"],"manufacturer_name":["PD-Rx Pharmaceuticals, Inc."],"application_number":["ANDA040586"],"original_packager_product_ndc":["69584-684","69584-685"]},"version":"9","warnings":["WARNINGS The abrupt withdrawal of antiepileptic medication may precipitate status epilepticus. The therapeutic efficacy of a dosage regimen takes several weeks before it can be assessed. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including primidone, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs. Table 1 Risk by indication for antiepileptic drugs in the pooled analysis Indication Placebo Patients with Events Per 1000 Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing primidone or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. Pregnancy To provide information regarding the effects of in utero exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ . The effects of primidone in human pregnancy and nursing infants are unknown. Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs. The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors leading to birth defects, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorders are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus. The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential. Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. Pregnant women under anticonvulsant therapy should receive prophylactic vitamin K1 therapy for one month prior to, and during, delivery."],"description":["DESCRIPTION Chemical name: 5-ethyldihydro-5-phenyl-4,6 (1H, 5H)-pyrimidinedione. Structural formula: Primidone is a white, crystalline, highly stable substance, M.P. 279-284°C. It is poorly soluble in water (60 mg per 100 mL at 37°C) and in most organic solvents. It possesses no acidic properties, in contrast to its barbiturate analog. Primidone 50 mg and 250 mg tablets contain the following inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate and talc. Primidone 250 mg tablets also contain D&C yellow #10 aluminum lake and FD&C yellow #5 aluminum lake. Structural Formula"],"precautions":["PRECAUTIONS The total daily dosage should not exceed 2 g. Since primidone therapy generally extends over prolonged periods, a complete blood count and a sequential multiple analysis-12 (SMA-12) test should be made every six months. Primidone Tablets 250 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. Nursing Mothers There is evidence in mothers treated with primidone, the drug appears in the milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of primidone-treated mothers be taken as an indication that nursing should be discontinued. Information for Patients Suicidal Thinking and Behavior - Patients, their caregivers, and families should be counseled that AEDs, including primidone, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self- harm. Behaviors of concern should be reported immediately to healthcare providers. Pregnancy - Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see WARNINGS, Pregnancy section). Please refer to the Primidone Tablets, USP Medication Guide provided with the product for more information."],"how_supplied":["HOW SUPPLIED Primidone 50 mg Tablets, USP are white, round, flat faced, beveled edge, scored tablets debossed \"684\" above bisect on one side and \"O\" on the other side. Supplied in: Bottles of 30, NDC 72789-178-30 Primidone 250 mg Tablets, USP are yellow, round, flat faced, beveled edge, scored tablets debossed \"685\" above bisect on one side and \"O\" on the other side. Supplied in: Bottles of 30, NDC 72789-177-30 Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container with a child-resistant closure. Dispense with Medication Guide available at:https://www.oxford-rx.com/med-guides"],"spl_medguide":["MEDICATION GUIDE Primidone Tablets, USP, 50 mg and 250 mg Dispense with Medication Guide available at: https://www.oxford-rx.com/med-guides Read this Medication Guide before you start taking primidone tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about primidone tablets? . Like other antiepileptic drugs, primidone tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood Do not stop primidone tablets without first talking to a healthcare provider. Stopping primidone tablets suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. What are primidone tablets? Primidone tablets are a prescription medicine used alone or with other medicines to treat people with: generalized tonic-clonic (grand mal) seizures complex partial (psychomotor) seizures partial (focal) epileptic seizures. Who should not take primidone tablets? Do not take primidone tablets if you: have a genetic disorder called porphyria are allergic to phenobarbital What should I tell my healthcare provider before taking primidone tablets? Before you take primidone tablets, tell your healthcare provider if you: have or have had depression, mood problems or suicidal thoughts or behavior have any other medical conditions are pregnant or planning to become pregnant. Primidone tablets may harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking primidone tablets. You and your healthcare provider will decide if you should take primidone tablets while you are pregnant. If you become pregnant while taking primidone tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. are breastfeeding or plan to breastfeed. Primidone can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take primidone tablets. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking primidone tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine. How should I take primidone tablets? Take primidone tablets exactly as prescribed. Your healthcare provider will tell you how much primidone tablets to take and when to take it. Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider. Do not stop taking primidone tablets without first talking to your healthcare provider. Stopping primidone tablets suddenly can cause serious problems. If you take too much primidone tablets, call your healthcare provider or local Poison Control Center right away. What should I avoid while taking primidone tablets? Primidone tablets can make you sleepy or dizzy. Do not drink alcohol or take other drugs that make you sleepy or dizzy while taking primidone tablets without first discussing this with your healthcare provider. Taking primidone tablets with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Do not drive, operate heavy machinery, or do other dangerous activities until you know how primidone tablets affect you. Primidone tablets can slow your thinking and motor skills. What are the possible side effects of primidone tablets? See “What is the most important information I should know about primidone tablets?”. Primidone tablets may cause other serious side effects including: Sleepiness that can be severe, especially when you first start taking primidone tablets. Primidone tablets may rarely cause blood problems. Symptoms may include: fever, swollen glands, or sore throat that come and go or do not go away frequent infections or an infection that does not go away tiredness shortness of breath Primidone tablets may rarely cause allergic reactions. Symptoms may include: skin rash hives sores in your mouth blistering or peeling skin The most common side effects of primidone tablets include: problems with walking and moving feelings of dizziness, spinning, or swaying (vertigo) These are not all the possible side effects of primidone tablets. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1- 800-FDA-1088. How should I store primidone tablets? Store primidone tablets at room temperature between 68°F to 77°F (20°C to 25°C) in a tight, light- resistant container. Keep primidone tablets and all medicines out of the reach of children. General Information about primidone tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use primidone tablets for a condition for which it was not prescribed. Do not give primidone tablets to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about primidone tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about primidone tablets that is written for health professionals. For more information, call 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday – Friday. What are the ingredients in Primidone? Active Ingredient: primidone Inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate and talc. Primidone 250 mg tablets also contain D&C yellow #10 aluminum lake and FD&C yellow #5 aluminum lake. Primidone Tablets 250 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. This Medication Guide has been approved by the U.S. Food and Drug Administration. Manufactured by: OXFORD PHARMACEUTICALS, LLC Birmingham, AL 35211 8200023 Rev 01 01/22"],"effective_time":"20250610","warnings_table":["
Table 1 Risk by indication for antiepileptic drugs in the pooled analysis
Indication
Placebo Patients with Events Per 1000 Patients
Drug Patients with Events Per 1000 Patients
Relative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo Patients
Risk Difference: Additional Drug Patients with Events Per 1000 Patients
Epilepsy
1.0
3.4
3.5
2.4
Psychiatric
5.7
8.5
1.5
2.9
Other
1.0
1.8
1.9
0.9
Total
2.4
4.3
1.8
1.9
"],"nursing_mothers":["Nursing Mothers There is evidence in mothers treated with primidone, the drug appears in the milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of primidone-treated mothers be taken as an indication that nursing should be discontinued."],"adverse_reactions":["ADVERSE REACTIONS The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness and morbilliform skin eruptions. Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistent or severe side effects may necessitate withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to primidone and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication. To report SUSPECTED ADVERSE REACTIONS, contact Oxford Pharmaceuticals, LLC at 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday – Friday or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Primidone is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital (see ACTIONS )."],"indications_and_usage":["INDICATIONS AND USAGE Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."],"information_for_patients":["Information for Patients Suicidal Thinking and Behavior - Patients, their caregivers, and families should be counseled that AEDs, including primidone, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self- harm. Behaviors of concern should be reported immediately to healthcare providers. Pregnancy - Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see WARNINGS, Pregnancy section). Please refer to the Primidone Tablets, USP Medication Guide provided with the product for more information."],"spl_unclassified_section":["ACTIONS Primidone raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone's antiepileptic action is not known. Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Usual Dosage Patients 8 years of age and older who have received no previous treatment may be started on primidone according to the following regimen using either 50 mg or scored 250 mg primidone tablets: Days 1 to 3: 100 to 125 mg at bedtime Days 4 to 6: 100 to 125 mg twice a day Days 7 to 9: 100 to 125 mg three times a day Day 10 to maintenance: 250 mg three times a day For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg primidone tablets in divided doses (250 mg t.i.d. or q.i.d.). If required, an increase to five or six 250 mg tablets daily may be made but daily doses should not exceed 500 mg q.i.d. Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations of primidone may be necessary for optimal dosage adjustment. The clinically effective serum level for primidone is between 5 to 12 µg/mL. INITIAL: ADULTS AND CHILDREN OVER 8 KEY: •=50 mg tablet; ●=250 mg tablet Day 1 2 3 4 5 6 AM •• •• •• NOON PM •• •• •• •• •• •• DAY 7 8 9 10 11 12 AM •• •• •• ● Adjust to Maintenance NOON •• •• •• ● PM •• •• •• ● Patients Already Receiving Other Anticonvulsants Primidone should be started at 100 to 125 mg at bedtime and gradually increased to maintenance level as the other drug is gradually decreased. This regimen should be continued until satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with primidone alone is the objective, the transition from concomitant therapy should not be completed in less than two weeks. Pediatric Dosage For children under 8 years of age, the following regimen may be used: Days 1 to 3: 50 mg at bedtime. Days 4 to 6: 50 mg twice a day Days 7 to 9: 100 mg twice a day Day 10 to maintenance: 125 mg three times a day to 250 mg three times a day For children under 8 years of age, the usual maintenance dosage is 125 to 250 mg three times daily or, 10 to 25 mg/kg/day in divided doses."],"spl_product_data_elements":["Primidone Primidone LACTOSE MONOHYDRATE HYPROMELLOSE 2910 (5 MPA.S) MICROCRYSTALLINE CELLULOSE 101 MAGNESIUM STEARATE SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO TALC PRIMIDONE PRIMIDONE 684;O Primidone Primidone LACTOSE MONOHYDRATE HYPROMELLOSE 2910 (5 MPA.S) MICROCRYSTALLINE CELLULOSE 101 MAGNESIUM STEARATE SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO TALC D&C YELLOW NO. 10 ALUMINUM LAKE FD&C YELLOW NO. 5 PRIMIDONE PRIMIDONE 685;O"],"dosage_and_administration_table":["
INITIAL: ADULTS AND CHILDREN OVER 8
KEY: •=50 mg tablet; ●=250 mg tablet
Day
1
2
3
4
5
6
AM
••
••
••
NOON
PM
••
••
••
••
••
••
DAY
7
8
9
10
11
12
AM
••
••
••
●
Adjust to Maintenance
NOON
••
••
••
●
PM
••
••
••
●
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Primidone Tablets, USP 50 mg ANTICONVULSANT EACH TABLET CONTAINS: Primidone, USP.................... 50 mg USUAL DOSAGE: See package insert. DISPENSE in a well-closed container with a child resistant closure. STORE at 20° to 25°C) (68° to 77°F) [see USP Controlled Room Temperature]. Keep out of reach of children. Primidone Tablets, USP 250 mg ANTICONVULSANT EACH TABLET CONTAINS: Primidone, USP.................... 250 mg Contains FD&C Yellow No. 5 (Tartrazine) as a color additive. USUAL DOSAGE: See package insert. DISPENSE in a well-closed container with a child resistant closure. STORE at 20° to 25C) (68° to 77°F) [see USP Controlled Room Temperature]. Keep out of reach of children. image image"]},"tags":[{"label":"Anti-epileptic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Transient receptor potential cation channel subfamily M member 3","category":"target"},{"label":"TRPM3","category":"gene"},{"label":"GABRA1","category":"gene"},{"label":"GABRB2","category":"gene"},{"label":"N03AA03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Bipolar disorder in remission","category":"indication"},{"label":"Epilepsy","category":"indication"},{"label":"Epilepsy characterized by intractable complex partial seizures","category":"indication"},{"label":"Lennox-Gastaut syndrome","category":"indication"},{"label":"Localization-related epilepsy","category":"indication"},{"label":"Simple partial seizure","category":"indication"},{"label":"Valeant","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"GABA Agents","category":"pharmacology"},{"label":"GABA Modulators","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":196.839,"date":"","count":215,"signal":"Seizure","source":"DrugCentral FAERS","actionTaken":"Reported 215 times (LLR=197)"},{"llr":124.507,"date":"","count":70,"signal":"Ataxia","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=125)"},{"llr":114.173,"date":"","count":153,"signal":"Tremor","source":"DrugCentral FAERS","actionTaken":"Reported 153 times (LLR=114)"},{"llr":107.28,"date":"","count":229,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 229 times (LLR=107)"},{"llr":90.423,"date":"","count":165,"signal":"Somnolence","source":"DrugCentral FAERS","actionTaken":"Reported 165 times (LLR=90)"},{"llr":88.049,"date":"","count":246,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 246 times (LLR=88)"},{"llr":68.72,"date":"","count":130,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 130 times (LLR=69)"},{"llr":63.353,"date":"","count":28,"signal":"Petit mal epilepsy","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=63)"},{"llr":60.56,"date":"","count":79,"signal":"Hallucination","source":"DrugCentral FAERS","actionTaken":"Reported 79 times (LLR=61)"},{"llr":50.785,"date":"","count":50,"signal":"Generalised tonic-clonic seizure","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=51)"},{"llr":48.461,"date":"","count":38,"signal":"Status epilepticus","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=48)"},{"llr":44.344,"date":"","count":14,"signal":"Cerebellar atrophy","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=44)"},{"llr":44.016,"date":"","count":74,"signal":"Balance disorder","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=44)"},{"llr":43.675,"date":"","count":46,"signal":"Serotonin syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=44)"},{"llr":42.789,"date":"","count":17,"signal":"Anticonvulsant drug level increased","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=43)"}],"drugInteractions":[{"url":"/drug/cyp1a2-substrates","drug":"CYP1A2 Substrates","action":"Use caution","effect":"Strong CYP1A2 Inducers - CYP1A2 Substrates","source":"DrugCentral","drugSlug":"cyp1a2-substrates"},{"url":"/drug/cyp2b6-substrates","drug":"CYP2B6 Substrates","action":"Use caution","effect":"Strong CYP2B6 Inducers - CYP2B6 Substrates","source":"DrugCentral","drugSlug":"cyp2b6-substrates"},{"url":"/drug/cyp2c8-substrates","drug":"CYP2C8 Substrates","action":"Use caution","effect":"Strong CYP2C8 Inducers - CYP2C8 Substrates","source":"DrugCentral","drugSlug":"cyp2c8-substrates"},{"url":"/drug/cyp2c9-substrates","drug":"CYP2C9 Substrates","action":"Use caution","effect":"Strong CYP2C9 Inducers - CYP2C9 Substrates","source":"DrugCentral","drugSlug":"cyp2c9-substrates"},{"url":"/drug/cyp3a4-substrates","drug":"CYP3A4 Substrates","action":"Use caution","effect":"Strong CYP3A4 Inducers - CYP3A4 Substrates","source":"DrugCentral","drugSlug":"cyp3a4-substrates"},{"url":"/drug/p-glycoprotein-substrates","drug":"P-glycoprotein Substrates","action":"Use caution","effect":"P-glycoprotein Inducers - P-glycoprotein Substrates","source":"DrugCentral","drugSlug":"p-glycoprotein-substrates"},{"url":"/drug/aripiprazole","drug":"aripiprazole","action":"Monitor closely","effect":"May interact with Aripiprazole","source":"DrugCentral","drugSlug":"aripiprazole"},{"url":"/drug/ciclosporin","drug":"ciclosporin","action":"Monitor closely","effect":"May interact with Cyclosporine","source":"DrugCentral","drugSlug":"ciclosporin"},{"url":"/drug/metronidazole","drug":"metronidazole","action":"Monitor closely","effect":"May interact with Metronidazole","source":"DrugCentral","drugSlug":"metronidazole"},{"url":"/drug/quetiapine","drug":"quetiapine","action":"Monitor closely","effect":"May interact with Quetiapine Fumarate","source":"DrugCentral","drugSlug":"quetiapine"},{"url":"/drug/sodium-oxybate","drug":"sodium oxybate","action":"Avoid combination","effect":"May interact with Sodium Oxybate","source":"DrugCentral","drugSlug":"sodium-oxybate"},{"url":"/drug/warfarin","drug":"warfarin","action":"Avoid combination","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"ataxia","drugRate":"reported","severity":"unknown"},{"effect":"vertigo","drugRate":"reported","severity":"unknown"},{"effect":"nausea","drugRate":"reported","severity":"unknown"},{"effect":"anorexia","drugRate":"reported","severity":"unknown"},{"effect":"vomiting","drugRate":"reported","severity":"unknown"},{"effect":"fatigue","drugRate":"reported","severity":"unknown"},{"effect":"hyperirritability","drugRate":"reported","severity":"unknown"},{"effect":"emotional disturbances","drugRate":"reported","severity":"unknown"},{"effect":"sexual impotency","drugRate":"reported","severity":"unknown"},{"effect":"diplopia","drugRate":"reported","severity":"unknown"},{"effect":"nystagmus","drugRate":"reported","severity":"unknown"},{"effect":"drowsiness","drugRate":"reported","severity":"unknown"},{"effect":"morbilliform skin eruptions","drugRate":"reported","severity":"unknown"},{"effect":"granulocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"red-cell hypoplasia and aplasia","drugRate":"reported","severity":"unknown"},{"effect":"megaloblastic anemia","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Alcoholism","Anemia","Aplastic anemia","Constitutional aplastic anemia","Depressive disorder","Disease of liver","Granulocytopenic disorder","Kidney disease","Leukopenia","Megaloblastic anemia","Neutropenic disorder","Non-infective meningitis","Pancytopenia","Porphyria","Pregnancy, function","Primidone Toxicity","Sleep apnea","Suicidal thoughts","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"Usage in Pregnancy. To provide information regarding the effects of in utero exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. The effects of primidone in human pregnancy"}},"trials":[],"aliases":[],"company":"Bausch Health","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3100/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$113","description":"PRIMIDONE 250 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PRIMIDONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:20:55.804951+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:21:01.397169+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PRIMIDONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:21:01.796008+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:54.691124+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:54.691151+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:54.691155+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:03.011967+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL856/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:02.641758+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA040586","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:20:54.691158+00:00"}},"allNames":"mysoline","offLabel":[],"synonyms":["desoxyphenobarbital","primidone","lepimidin","primaclone","primacone"],"timeline":[{"date":"1954-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from VALEANT to Valeant"},{"date":"1954-03-08","type":"positive","source":"DrugCentral","milestone":"FDA approval (Valeant)"}],"aiSummary":"Mysoline (Primidone) is an anti-epileptic agent developed by Valeant, targeting the transient receptor potential cation channel subfamily M member 3. It is a small molecule modality approved by the FDA in 1954 for various seizure disorders, including epilepsy and bipolar disorder in remission. Mysoline is available as a generic medication, with multiple manufacturers, and is off-patent. As an anti-epileptic agent, Mysoline is used to control seizures and prevent their recurrence. It is essential to monitor patients for potential side effects and interactions.","approvals":[{"date":"1954-03-08","orphan":false,"company":"VALEANT","regulator":"FDA"}],"brandName":"Mysoline","ecosystem":[{"indication":"Bipolar disorder in remission","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"lamotrigine","slug":"lamotrigine","company":"Glaxosmithkline Llc"},{"name":"lithium carbonate","slug":"lithium-carbonate","company":""}],"globalPrevalence":40000000},{"indication":"Epilepsy","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"diazepam","slug":"diazepam","company":"Roche"},{"name":"felbamate","slug":"felbamate","company":"Meda Pharms"}],"globalPrevalence":50000000},{"indication":"Epilepsy characterized by intractable complex partial seizures","otherDrugs":[{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"ethotoin","slug":"ethotoin","company":"Recordati Rare"},{"name":"fosphenytoin","slug":"fosphenytoin","company":"Parke Davis"},{"name":"lamotrigine","slug":"lamotrigine","company":"Glaxosmithkline Llc"}],"globalPrevalence":50000000},{"indication":"Lennox-Gastaut syndrome","otherDrugs":[{"name":"cannabidiol","slug":"cannabidiol","company":"Gw Research Ltd"},{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"clobazam","slug":"clobazam","company":"Lundbeck Llc"},{"name":"clonazepam","slug":"clonazepam","company":"Roche"}],"globalPrevalence":1200000},{"indication":"Localization-related epilepsy","otherDrugs":[{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"mephenytoin","slug":"mephenytoin","company":"Novartis"},{"name":"oxcarbazepine","slug":"oxcarbazepine","company":"Novartis"},{"name":"phenytoin","slug":"phenytoin","company":"Parke Davis"}],"globalPrevalence":50000000},{"indication":"Simple partial seizure","otherDrugs":[{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"felbamate","slug":"felbamate","company":"Meda Pharms"},{"name":"lamotrigine","slug":"lamotrigine","company":"Glaxosmithkline Llc"},{"name":"levetiracetam","slug":"levetiracetam","company":"Ucb Inc"}],"globalPrevalence":null},{"indication":"Tonic-clonic epilepsy","otherDrugs":[{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"ethotoin","slug":"ethotoin","company":"Recordati Rare"},{"name":"metharbital","slug":"metharbital","company":"Abbvie"},{"name":"phenytoin","slug":"phenytoin","company":"Parke Davis"}],"globalPrevalence":50000000},{"indication":"Tonic-clonic seizure","otherDrugs":[{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"lamotrigine","slug":"lamotrigine","company":"Glaxosmithkline Llc"},{"name":"phenytoin","slug":"phenytoin","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"target":"Transient receptor potential cation channel subfamily M member 3","novelty":"First-in-class","targets":[{"gene":"TRPM3","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily M member 3","protein":"Transient receptor potential cation channel subfamily M member 3"},{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRB2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-2"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"}],"modality":"Small Molecule","drugClass":"Anti-epileptic Agent [EPC]","explanation":"","oneSentence":"","technicalDetail":"Primidone is a barbiturate derivative that acts as a GABA_A receptor agonist, enhancing the inhibitory effects of GABA on neuronal excitability, thereby reducing the frequency and severity of seizures."},"commercial":{"launchDate":"1954","_launchSource":"DrugCentral (FDA 1954-03-08, VALEANT)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2267","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PRIMIDONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PRIMIDONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:28:36.333030","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:05.485214+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metharbital","drugSlug":"metharbital","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"primidone","indications":{"approved":[{"name":"Bipolar disorder in remission","source":"DrugCentral","snomedId":85248005,"regulator":"FDA","eligibility":null,"usPrevalence":7000000,"globalPrevalence":40000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"},{"name":"Epilepsy","source":"DrugCentral","snomedId":84757009,"regulator":"FDA","eligibility":null,"usPrevalence":3400000,"globalPrevalence":50000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Epilepsy characterized by intractable complex partial seizures","source":"DrugCentral","snomedId":442481002,"regulator":"FDA","eligibility":null,"usPrevalence":3400000,"globalPrevalence":50000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Lennox-Gastaut syndrome","source":"DrugCentral","snomedId":230418006,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":1200000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet ([EXPERT]_European Medicines Agency 2004[INST])"},{"name":"Localization-related epilepsy","source":"DrugCentral","snomedId":230381009,"regulator":"FDA","eligibility":null,"usPrevalence":3400000,"globalPrevalence":50000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Simple partial seizure","source":"DrugCentral","snomedId":117891000119100,"regulator":"FDA","eligibility":null},{"name":"Tonic-clonic epilepsy","source":"DrugCentral","snomedId":352818000,"regulator":"FDA","eligibility":null,"usPrevalence":3400000,"globalPrevalence":50000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Tonic-clonic seizure","source":"DrugCentral","snomedId":54200006,"regulator":"FDA","eligibility":null}],"offLabel":[{"name":"Bipolar affective disorder, current episode depression","source":"DrugCentral","drugName":"PRIMIDONE"},{"name":"Essential tremor","source":"DrugCentral","drugName":"PRIMIDONE","evidenceCount":200,"evidenceLevel":"strong"},{"name":"Neuropathic pain","source":"DrugCentral","drugName":"PRIMIDONE"},{"name":"Rapid Cycling Bipolar Affective Disorder","source":"DrugCentral","drugName":"PRIMIDONE","evidenceCount":2,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Valeant","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"metharbital","brandName":"metharbital","genericName":"metharbital","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03196466","phase":"","title":"Population Pharmacokinetics of Antiepileptic in Pediatrics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-19","conditions":["Epilepsy"],"enrollment":753,"completionDate":"2023-06-15"},{"nctId":"NCT07212244","phase":"","title":"Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10","conditions":["Essential Tremor","Essential Tremor, Movement Disorders"],"enrollment":240,"completionDate":"2032-09"},{"nctId":"NCT07006740","phase":"","title":"Safety and Effectiveness of Unilateral MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor","status":"NOT_YET_RECRUITING","sponsor":"meishanshan","startDate":"2025-06-10","conditions":["Essential Tremor"],"enrollment":100,"completionDate":"2027-06-10"},{"nctId":"NCT04692844","phase":"","title":"Pathophysiology of Tremor-modulating Mechanisms of Propranolol and Primidone in Essential Tremor","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2017-08-28","conditions":["Essential Tremor"],"enrollment":61,"completionDate":"2022-12-31"},{"nctId":"NCT00404248","phase":"PHASE1,PHASE2","title":"Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-01","conditions":["Brain and Central Nervous System Tumors"],"enrollment":35,"completionDate":"2012-02"},{"nctId":"NCT02008123","phase":"PHASE2","title":"Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant","status":"WITHDRAWN","sponsor":"Dent Neuroscience Research Center","startDate":"2013-08","conditions":["Clopidogrel Resistance","Secondary Stroke Prevention"],"enrollment":0,"completionDate":""},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":["Brain and Central Nervous System Tumors"],"enrollment":35,"completionDate":"2006-05"},{"nctId":"NCT00734864","phase":"PHASE1","title":"Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"Annick Desjardins","startDate":"2009-06","conditions":["Glioblastoma Multiforme","Gliosarcoma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Glioma"],"enrollment":0,"completionDate":"2012-06"},{"nctId":"NCT01390909","phase":"","title":"Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":["Epilepsy"],"enrollment":12386,"completionDate":"2011-01"},{"nctId":"NCT01132040","phase":"PHASE1","title":"Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2006-08","conditions":["Healthy"],"enrollment":24,"completionDate":"2006-09"},{"nctId":"NCT00685165","phase":"PHASE1","title":"Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2004-05","conditions":["Therapeutic Equivalency"],"enrollment":22,"completionDate":"2004-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"PRIMIDONE"},{"form":"TABLET","route":"ORAL","productName":"Primidone"},{"form":"TABLET","route":"ORAL","productName":"Mysoline"},{"form":"TABLET","route":"ORAL","productName":"Primidone"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146807","MMSL":"390","NDDF":"001626","UNII":"13AFD7670Q","VUID":"4018485","CHEBI":"CHEBI:8412","VANDF":"4018485","INN_ID":"248","RXNORM":"8691","UMLSCUI":"C0033148","chemblId":"CHEMBL856","ChEMBL_ID":"CHEMBL856","KEGG_DRUG":"D00474","DRUGBANK_ID":"DB00794","PUBCHEM_CID":"4909","SNOMEDCT_US":"387256009","IUPHAR_LIGAND_ID":"5338","MESH_DESCRIPTOR_UI":"D011324"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1954-","companyName":"Valeant","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"92%"},"publicationCount":1331,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"N03AA03","allCodes":["N03AA03"]},"biosimilarFilings":[],"originalDeveloper":"Valeant","recentPublications":[{"date":"2026 Mar 21","pmid":"41897256","title":"Comparative Efficacy of Acupuncture Therapy in Primary Essential Tremor: A Network Meta-Analysis and Systematic Review.","journal":"Healthcare (Basel, Switzerland)"},{"date":"2026 Apr","pmid":"41833537","title":"A Systematic Review of Clinically Significant Drug-Drug Interactions With Phenobarbital and Primidone.","journal":"Pharmacotherapy"},{"date":"2026 Mar 17","pmid":"41806836","title":"TRPM3 mediates spontaneous pain and mechanical allodynia in a mouse model of chronic orofacial neuropathy.","journal":"Cell reports. Medicine"},{"date":"2026 Apr 10","pmid":"41795508","title":"Enteric virus and pharmaceutical and personal care product attenuation in a bench-scale ozone-soil aquifer treatment process.","journal":"The Science of the total environment"},{"date":"2026 Jan 20","pmid":"41556478","title":"Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.","journal":"Movement disorders : official journal of the Movement Disorder Society"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Amneal Pharm","Carnegie","Chartwell Rx","Hikma Intl Pharms","Impax Labs","Lannett","Oxford Pharms","Rubicon Research","Tp Anda Holdings","Watson Labs"],"status":"approved","companyName":"Valeant","companyId":"bausch","modality":"Small molecule","firstApprovalDate":"1954","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1954-03-08T00:00:00.000Z","mah":"VALEANT","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:05.485214+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}